Publication
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.
Authors not recorded
J Clin Oncol2021PMID 33750196PMC8189627stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerHead and Neck Squamous Cell Carcinomacivic_curation1.00
- drugTipifarnibcivic_curation1.00
- geneHRAScivic_curation1.00
- variantHRAS Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 33750196
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| HRAS Mutation1 | ||||||||
| Tipifarnib | Head and Neck Squamous Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID9633In a phase II HNSCC trial, an objective response rate of 55% was seen in HRAS-mutant patients (11 of 20) treated with the farnesyltransferase inhibitor tipifarnib with a PFS of 5.6 months and an OS of… (full text at CIViC) PMID 33750196 · Ho et al., 2021 · Open in CIViC | civic |